Galectin Therapeutics Inc (GALT) Stock Price & Analysis

Galectin Therapeutics Inc (GALT) rose 0.42% to USD 2.41 as of June 10, 2026 at 08:28 UTC, according to Nexqual real-time market data.

GALT last closed at USD 2.4; the session ranged USD 2.38–2.54 on volume of 294,780 shares. Market capitalization is $158.72M, with a 52-week range of USD 1.31–7.13 (NCM). Source: Nexqual, June 10, 2026 at 08:28 UTC.

Key Statistics (as of June 10, 2026 at 08:28 UTC)

Technical Analysis (GALT)

Nexqual's technical model rates GALT "NEUTRAL" based on 3 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 08:28 UTC.

Analyst Ratings (GALT)

Wall Street analysts rate GALT "Strong Buy" based on 1 analysts, with a mean price target of USD 11 (range USD 11–11), per Nexqual as of June 10, 2026 at 08:28 UTC.

Earnings (GALT)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 08:28 UTC.

Financials & Fundamentals (GALT)

Source: Nexqual, June 10, 2026 at 08:28 UTC.

Financial Health Score (GALT)

Nexqual rates Galectin Therapeutics Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 08:28 UTC.

Ownership (GALT)

Source: Nexqual, June 10, 2026 at 08:28 UTC.

Leadership (GALT)

Galectin Therapeutics Inc is led by Joel Lewis (age 55), President & CEO, per Nexqual as of June 10, 2026 at 08:28 UTC.

Major Backers & Investors (GALT)

Notable institutional backers of Galectin Therapeutics Inc include Marshall Wace LLP, Osaic Holdings Inc., Millennium Management, according to Nexqual as of June 10, 2026 at 08:28 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 08:28 UTC.

From Galectin Therapeutics Inc's Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• We filed an IND with FDA and are planning a phase 2 trial to be filed with the FDA oncology division, dependent in part on finding a suitable partner or obtaining financing for the trial.   9 Index Patents and Proprietary Rights   Our development and commercial viability, and ultimately our competitiveness, depend on our ability to develop and maintain the proprietary aspects of our technology and operate without infringing on the proprietary rights of others.
• Failure to comply with the applicable U.S. requirements may subject us to administrative or judicial sanctions, such as FDA refusal to approve pending New Drug Applications ("NDAs"), warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, and/or criminal prosecution.   Drug Approval Process   Drugs may not be marketed in the U.S. until the FDA has approved them.
• We seek to protect our intellectual property by requiring employees, consultants, and any third parties with access to our proprietary information to execute confidentiality agreements and by restricting access to that information.   In August 2015, we received a notice of allowance from the U.S.
• To have our products manufactured, we have developed and will continue to develop relationships with third-parties that have established pharmaceutical manufacturing capabilities and expertise.

Partnerships

• We are not a party to any long-term agreement with any of our suppliers and, accordingly, we have our products manufactured on a purchase-order basis from one of two primary well-known and established pharmaceutical suppliers that meet FDA requirements.
• On April 25, 2001, DTR-Med Pharma Corp. ("DTR"), which was incorporated in Nevada on January 26, 2001, entered into a stock exchange agreement with Pro-Pharmaceuticals, Inc., whereby DTR acquired all of the outstanding shares of common stock of Pro-Pharmaceuticals, Inc.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:28 UTC. This page is informational and not investment advice.